merck to acquire argenx

Quote





No chance. Argenx is not worth the 50B premium it would take to acquire. Single asset company that is about to learn a very harsh lesson in what home administration of their drug does to the bottom line.
 


anonymous said:
No chance. Argenx is not worth the 50B premium it would take to acquire. Single asset company that is about to learn a very harsh lesson in what home administration of their drug does to the bottom line.
Click to expand...
$50B? More like $7B. Market gonna get more crowded soon. Still a nice premium to shares outstanding.
 


anonymous said:
$50B? More like $7B. Market gonna get more crowded soon. Still a nice premium to shares outstanding.
Click to expand...
It would be more like a 60% premium ($23B at current share price of $630) which would put the SP at just over $1000/share for a BO at $61.4B! Problem is there is a price target is at $1,100 so I doubt company would take less than $70B in a BO...
 


anonymous said:
It would be more like a 60% premium ($23B at current share price of $630) which would put the SP at just over $1000/share for a BO at $61.4B! Problem is there is a price target is at $1,100 so I doubt company would take less than $70B in a BO...
Click to expand...
Never gonna happen. Rates are too high to finance that on a probability that 2030 would work out. Risk premium just is not there. No pharma compound or company is carrying that much. If it was, it would be bullet proof and just self finance or acquire and grow.

Best best - sold off in sections or acquired as whole with modest discount. Either way, M&A with pharma are gonna get a sideways glance. Very limited upstream activity now.

Nice commercials though. Fun to see see your org already auditioning for big pharma with your storyboard/patient journey commercials. Cannot wait to see the next one.
 


Nah. Merck will want a company with strong Phase 2 oncology assets to replace Keytruda when it goes off patent. The immunology products from Argenx just aren’t that strong, and the disease states the company treats are not common enough to build a revenue base wide enough to capitalize an acquisition that narrow. Your fantasies are good, though.
 


anonymous said:
Nah. Merck will want a company with strong Phase 2 oncology assets to replace Keytruda when it goes off patent. The immunology products from Argenx just aren’t that strong, and the disease states the company treats are not common enough to build a revenue base wide enough to capitalize an acquisition that narrow. Your fantasies are good, though.
Click to expand...
Abbv owns those asset rights.
 















Write your reply...
Top Bottom
Back
Quote